APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication

Cell Reports

Volumn 14, Issue 6, 2016, Pages 1273-1282

  Hoopes, James I ^a   Cortez, Luis M ^a   Mertz, Tony M ^a   Malc, Ewa P ^b   Mieczkowski, Piotr A ^b   Roberts, Steven A ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3A; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3B; CYTIDINE DEAMINASE; SINGLE STRANDED DNA; UNCLASSIFIED DRUG; APOBEC3A PROTEIN, HUMAN; APOBEC3B PROTEIN, HUMAN; FUNGAL DNA; MINOR HISTOCOMPATIBILITY ANTIGEN; PROTEIN; TUMOR PROTEIN;

ARTICLE; CONTROLLED STUDY; DEAMINATION; DNA REPLICATION; DNA TEMPLATE; ENZYME SUBSTRATE; GENE SEQUENCE; MUTAGENESIS; MUTATOR GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; TUMOR GENE; YEAST; CHEMISTRY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; METABOLISM; MUTATION; NEOPLASM; PLASMID; SACCHAROMYCES CEREVISIAE; SIGNAL TRANSDUCTION; TRANSGENE;

CYTIDINE DEAMINASE; DEAMINATION; DNA REPLICATION; DNA, FUNGAL; DNA, SINGLE-STRANDED; GENE EXPRESSION REGULATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MINOR HISTOCOMPATIBILITY ANTIGENS; MUTAGENESIS; MUTATION; NEOPLASM PROTEINS; NEOPLASMS; PLASMIDS; PROTEINS; SACCHAROMYCES CEREVISIAE; SIGNAL TRANSDUCTION; TRANSFECTION; TRANSGENES;

EID: 84955622630     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.01.021     Document Type: Article

References (69)

1. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A., Behjati S., Biankin A.V., Bignell G.R., Bolli N., Borg A., Børresen-Dale A.L., et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421. Australian Pancreatic Cancer Genome Initiative, ICGC Breast Cancer ConsortiumICGC Breast Cancer Consortium, ICGC MMML-Seq ConsortiumICGC MMML-Seq Consortium, ICGC PedBrainICGC PedBrain.
2. Balakrishnan L., Bambara R.A. Eukaryotic lagging strand DNA replication employs a multi-pathway mechanism that protects genome integrity. J. Biol. Chem. 2011, 286:6865-6870.
3. Bellí G., Garí E., Piedrafita L., Aldea M., Herrero E. An activator/repressor dual system allows tight tetracycline-regulated gene expression in budding yeast. Nucleic Acids Res. 1998, 26:942-947.
4. Bhagwat A.S., Hao W., Townes J.P., Lee H., Tang H., Foster P.L. Strand-biased cytosine deamination at the replication fork causes cytosine to thymine mutations in Escherichia coli. Proc. Natl. Acad. Sci. USA 2016, 10.1073/pnas.1522325113.
5. Bianchi V., Pontis E., Reichard P. Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J. Biol. Chem. 1986, 261:16037-16042.
6. Bogerd H.P., Wiegand H.L., Hulme A.E., Garcia-Perez J.L., O'Shea K.S., Moran J.V., Cullen B.R. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc. Natl. Acad. Sci. USA 2006, 103:8780-8785.
7. Bransteitter R., Pham P., Scharff M.D., Goodman M.F. Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc. Natl. Acad. Sci. USA 2003, 100:4102-4107.
8. Burns M.B., Lackey L., Carpenter M.A., Rathore A., Land A.M., Leonard B., Refsland E.W., Kotandeniya D., Tretyakova N., Nikas J.B., et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 2013, 494:366-370.
9. Burns M.B., Temiz N.A., Harris R.S. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 2013, 45:977-983.
10. Caval V., Suspène R., Shapira M., Vartanian J.P., Wain-Hobson S. A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage. Nat. Commun. 2014, 5:5129.
11. Chan K., Roberts S.A., Klimczak L.J., Sterling J.F., Saini N., Malc E.P., Kim J., Kwiatkowski D.J., Fargo D.C., Mieczkowski P.A., et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat. Genet. 2015, 47:1067-1072.
12. Chaudhuri J., Tian M., Khuong C., Chua K., Pinaud E., Alt F.W. Transcription-targeted DNA deamination by the AID antibody diversification enzyme. Nature 2003, 422:726-730.
13. Chaudhuri J., Khuong C., Alt F.W. Replication protein A interacts with AID to promote deamination of somatic hypermutation targets. Nature 2004, 430:992-998.
14. Chen H., Lilley C.E., Yu Q., Lee D.V., Chou J., Narvaiza I., Landau N.R., Weitzman M.D. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr. Biol. 2006, 16:480-485.
15. Choder M., Aloni Y. RNA polymerase II allows unwinding and rewinding of the DNA and thus maintains a constant length of the transcription bubble. J. Biol. Chem. 1988, 263:12994-13002.
16. Chung W.H., Zhu Z., Papusha A., Malkova A., Ira G. Defective resection at DNA double-strand breaks leads to de novo telomere formation and enhances gene targeting. PLoS Genet. 2010, 6:e1000948.
17. Crooks G.E., Hon G., Chandonia J.M., Brenner S.E. WebLogo: a sequence logo generator. Genome Res. 2004, 14:1188-1190.
18. Deng S.K., Gibb B., de Almeida M.J., Greene E.C., Symington L.S. RPA antagonizes microhomology-mediated repair of DNA double-strand breaks. Nat. Struct. Mol. Biol. 2014, 21:405-412.
19. Haradhvala N., Polak P., Stojanov P., Covington K.R., Shinbrot E., Hess J., Rheinbay E., Kim J., Maruvka Y., Braunstein L.Z., et al. Mutational strand asymmetries across cancer reveal mechanisms of DNA damage and repair. Cell 2016, 164:538-549.
20. Hayano M., Kanoh Y., Matsumoto S., Masai H. Mrc1 marks early-firing origins and coordinates timing and efficiency of initiation in fission yeast. Mol. Cell. Biol. 2011, 31:2380-2391.
21. Hills S.A., Diffley J.F. DNA replication and oncogene-induced replicative stress. Curr. Biol. 2014, 24:R435-R444.
22. Jackson S.P., Bartek J. The DNA-damage response in human biology and disease. Nature 2009, 461:1071-1078.
23. Katou Y., Kanoh Y., Bando M., Noguchi H., Tanaka H., Ashikari T., Sugimoto K., Shirahige K. S-phase checkpoint proteins Tof1 and Mrc1 form a stable replication-pausing complex. Nature 2003, 424:1078-1083.
24. Kazanov M.D., Roberts S.A., Polak P., Stamatoyannopoulos J., Klimczak L.J., Gordenin D.A., Sunyaev S.R. APOBEC-induced cancer mutations are uniquely enriched in early-replicating, gene-dense, and active chromatin regions. Cell Rep. 2015, 13:1103-1109.
25. Kidd J.M., Newman T.L., Tuzun E., Kaul R., Eichler E.E. Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet. 2007, 3:e63.
26. Komatsu A., Nagasaki K., Fujimori M., Amano J., Miki Y. Identification of novel deletion polymorphisms in breast cancer. Int. J. Oncol. 2008, 33:261-270.
27. Lada A.G., Waisertreiger I.S., Grabow C.E., Prakash A., Borgstahl G.E., Rogozin I.B., Pavlov Y.I. Replication protein A (RPA) hampers the processive action of APOBEC3G cytosine deaminase on single-stranded DNA. PLoS ONE 2011, 6:e24848.
28. Lada A.G., Kliver S.F., Dhar A., Polev D.E., Masharsky A.E., Rogozin I.B., Pavlov Y.I. Disruption of transcriptional coactivator Sub1 leads to genome-wide re-distribution of clustered mutations induced by APOBEC in active yeast genes. PLoS Genet. 2015, 11:e1005217.
29. Landry S., Narvaiza I., Linfesty D.C., Weitzman M.D. APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. EMBO Rep. 2011, 12:444-450.
30. Liu M., Duke J.L., Richter D.J., Vinuesa C.G., Goodnow C.C., Kleinstein S.H., Schatz D.G. Two levels of protection for the B cell genome during somatic hypermutation. Nature 2008, 451:841-845.
31. Love R.P., Xu H., Chelico L. Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A. J. Biol. Chem. 2012, 287:30812-30822.
32. Lujan S.A., Clausen A.R., Clark A.B., MacAlpine H.K., MacAlpine D.M., Malc E.P., Mieczkowski P.A., Burkholder A.B., Fargo D.C., Gordenin D.A., Kunkel T.A. Heterogeneous polymerase fidelity and mismatch repair bias genome variation and composition. Genome Res. 2014, 24:1751-1764.
33. Macheret M., Halazonetis T.D. DNA replication stress as a hallmark of cancer. Annu. Rev. Pathol. 2015, 10:425-448.
34. Morrison A., Bell J.B., Kunkel T.A., Sugino A. Eukaryotic DNA polymerase amino acid sequence required for 3'----5' exonuclease activity. Proc. Natl. Acad. Sci. USA 1991, 88:9473-9477.
35. Narvaiza I., Landry S., Weitzman M.D. APOBEC3 proteins and genomic stability: the high cost of a good defense. Cell Cycle 2012, 11:33-38.
36. Nik-Zainal S., Alexandrov L.B., Wedge D.C., Van Loo P., Greenman C.D., Raine K., Jones D., Hinton J., Marshall J., Stebbings L.A., et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012, 149:979-993. Breast Cancer Working Group of the International Cancer Genome Consortium.
37. Nordentoft I., Lamy P., Birkenkamp-Demtröder K., Shumansky K., Vang S., Hornshøj H., Juul M., Villesen P., Hedegaard J., Roth A., et al. Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep. 2014, 7:1649-1663.
38. Pal M., Ponticelli A.S., Luse D.S. The role of the transcription bubble and TFIIB in promoter clearance by RNA polymerase II. Mol. Cell 2005, 19:101-110.
39. Pavri R., Gazumyan A., Jankovic M., Di Virgilio M., Klein I., Ansarah-Sobrinho C., Resch W., Yamane A., Reina San-Martin B., Barreto V., et al. Activation-induced cytidine deaminase targets DNA at sites of RNA polymerase II stalling by interaction with Spt5. Cell 2010, 143:122-133.
40. Peters A., Storb U. Somatic hypermutation of immunoglobulin genes is linked to transcription initiation. Immunity 1996, 4:57-65.
41. Pham P., Bransteitter R., Petruska J., Goodman M.F. Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. Nature 2003, 424:103-107.
42. Pham P., Chelico L., Goodman M.F. DNA deaminases AID and APOBEC3G act processively on single-stranded DNA. DNA Repair (Amst.) 2007, 6:689-692. author reply 693-694.
43. Pham P., Landolph A., Mendez C., Li N., Goodman M.F. A biochemical analysis linking APOBEC3A to disparate HIV-restriction and skin cancer. J. Biol. Chem. 2013, 288:29294-29304.
44. Poli J., Tsaponina O., Crabbé L., Keszthelyi A., Pantesco V., Chabes A., Lengronne A., Pasero P. dNTP pools determine fork progression and origin usage under replication stress. EMBO J. 2012, 31:883-894.
45. Ramiro A.R., Stavropoulos P., Jankovic M., Nussenzweig M.C. Transcription enhances AID-mediated cytidine deamination by exposing single-stranded DNA on the nontemplate strand. Nat. Immunol. 2003, 4:452-456.
46. Reddy J.P., Peddibhotla S., Bu W., Zhao J., Haricharan S., Du Y.C., Podsypanina K., Rosen J.M., Donehower L.A., Li Y. Defining the ATM-mediated barrier to tumorigenesis in somatic mammary cells following ErbB2 activation. Proc. Natl. Acad. Sci. USA 2010, 107:3728-3733.
47. Refsland E.W., Harris R.S. The APOBEC3 family of retroelement restriction factors. Curr. Top. Microbiol. Immunol. 2013, 371:1-27.
48. Roberts S.A., Sterling J., Thompson C., Harris S., Mav D., Shah R., Klimczak L.J., Kryukov G.V., Malc E., Mieczkowski P.A., et al. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol. Cell 2012, 46:424-435.
49. Roberts S.A., Lawrence M.S., Klimczak L.J., Grimm S.A., Fargo D., Stojanov P., Kiezun A., Kryukov G.V., Carter S.L., Saksena G., et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 2013, 45:970-976.
50. Sakofsky C.J., Roberts S.A., Malc E., Mieczkowski P.A., Resnick M.A., Gordenin D.A., Malkova A. Break-induced replication is a source of mutation clusters underlying kataegis. Cell Rep. 2014, 7:1640-1648.
51. Saraconi G., Severi F., Sala C., Mattiuz G., Conticello S.G. The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas. Genome Biol. 2014, 15:417.
52. Sherman F., Fink G.F., Hicks J.B. Methods in Yeast Genetics 1986, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
53. Shibata D., Lieber M.R. Is there any genetic instability in human cancer?. DNA Repair (Amst.) 2010, 9:858. discussion 859-860.
54. Slater M.L. Effect of reversible inhibition of deoxyribonucleic acid synthesis on the yeast cell cycle. J. Bacteriol. 1973, 113:263-270.
55. Smith D.J., Whitehouse I. Intrinsic coupling of lagging-strand synthesis to chromatin assembly. Nature 2012, 483:434-438.
56. Suspène R., Sommer P., Henry M., Ferris S., Guétard D., Pochet S., Chester A., Navaratnam N., Wain-Hobson S., Vartanian J.P. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res. 2004, 32:2421-2429.
57. Taylor B.J., Nik-Zainal S., Wu Y.L., Stebbings L.A., Raine K., Campbell P.J., Rada C., Stratton M.R., Neuberger M.S. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. eLife 2013, 2:e00534.
58. Taylor B.J., Wu Y.L., Rada C. Active RNAP pre-initiation sites are highly mutated by cytidine deaminases in yeast, with AID targeting small RNA genes. eLife 2014, 3:e03553.
59. Teng B., Burant C.F., Davidson N.O. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 1993, 260:1816-1819.
60. Thielen B.K., McNevin J.P., McElrath M.J., Hunt B.V., Klein K.C., Lingappa J.R. Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J. Biol. Chem. 2010, 285:27753-27766.
61. Toledo L.I., Altmeyer M., Rask M.B., Lukas C., Larsen D.H., Povlsen L.K., Bekker-Jensen S., Mailand N., Bartek J., Lukas J. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell 2013, 155:1088-1103.
62. Tourrière H., Versini G., Cordón-Preciado V., Alabert C., Pasero P. Mrc1 and Tof1 promote replication fork progression and recovery independently of Rad53. Mol. Cell 2005, 19:699-706.
63. Waters C.E., Saldivar J.C., Amin Z.A., Schrock M.S., Huebner K. FHIT loss-induced DNA damage creates optimal APOBEC substrates: insights into APOBEC-mediated mutagenesis. Oncotarget 2015, 6:3409-3419.
64. Willmann K.L., Milosevic S., Pauklin S., Schmitz K.M., Rangam G., Simon M.T., Maslen S., Skehel M., Robert I., Heyer V., et al. A role for the RNA pol II-associated PAF complex in AID-induced immune diversification. J. Exp. Med. 2012, 209:2099-2111.
65. Xuan D., Li G., Cai Q., Deming-Halverson S., Shrubsole M.J., Shu X.O., Kelley M.C., Zheng W., Long J. APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry. Carcinogenesis 2013, 34:2240-2243.
66. Yu Q., König R., Pillai S., Chiles K., Kearney M., Palmer S., Richman D., Coffin J.M., Landau N.R. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 2004, 11:435-442.
67. Zeman M.K., Cimprich K.A. Causes and consequences of replication stress. Nat. Cell Biol. 2014, 16:2-9.
68. Zheng S., Vuong B.Q., Vaidyanathan B., Lin J.Y., Huang F.T., Chaudhuri J. Non-coding RNA generated following Lariat debranching mediates targeting of AID to DNA. Cell 2015, 161:762-773.
69. Zhou Y., Caron P., Legube G., Paull T.T. Quantitation of DNA double-strand break resection intermediates in human cells. Nucleic Acids Res. 2014, 42:e19.